Gate2Brain has reached a major milestone as its innovative drug, G2B-002, has received Orphan Drug Designation
i4KIDS I i4KIDS-EUROPE shared on LinkedIn:
”We have great news for paediatric innovation!
Gate2Brain, a spin-off from the IRB Barcelona, The University of Barcelona and Sant Joan de Deu Barcelona Hospital, has reached a major milestone as its innovative drug, G2B-002, has received Orphan Drug Designation from the European Medicines Agency – a remarkable step towards advancing therapies for aggressive brain tumours such as DIPG and pGBM.
Gate2Brain is now launching a bridge financing round to raise €1.5 million in convertible notes open to national and international business angels and family offices. These funds will support the finishing of the preclinical regulatory progress needed before entering clinical trials, bringing hope for breakthrough treatments in paediatric neuro-oncology.
At i4KIDS, we’re proud to stand alongside the Gate2Brain team in their mission to transform childhood cancer care!”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023